Shire Expects Next-Generation Adderall XR Approval Following DEA Scheduling
This article was originally published in The Pink Sheet Daily
Executive Summary
"Approvable" letter from FDA says marketing approval of NRP-104 is contingent upon final scheduling by DEA.
You may also be interested in...
Shire Confident Of Vyvanse Approval, Despite Second ‘Approvable’ Letter
Adderall XR follow-on still slated for Q2 2007 launch.
Shire Confident Of Vyvanse Approval, Despite Second ‘Approvable’ Letter
Adderall XR follow-on still slated for Q2 2007 launch.
Shire Patent Infringement Suit Over Adderall XR Triggers 30-Month Stay
Stay of FDA action on Andrx' ANDA will extend beyond Barr's entry, Shire says.